Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug
Post# of 420
(Total Views: 232)
Posted On: 10/05/2021 4:30:28 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage
- Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share
- Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs
- Lexaria is also investigating alternatives to smoked or inhaled nicotine delivery to avoid lung harm, expanding the potential of its technology
- DehydraTECH’s lymph system delivery method alternative to the digestive system provides more rapid bioavailability and fewer side effects, as well as the potential for better delivery across the blood-brain barrier
- The relatively low-cost technology has the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships
Oral drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) has drawn the attention of Zacks Small-Cap Research analysts, who have initiated coverage of Lexaria with a valuation of $15 per share because of the company’s patent portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption technology and the multiple potential uses of the technology.
DehydraTECH pairs active pharmaceutical ingredients (“APIs”) with select long-chain fatty acid (“LCFAs”) oils that serve as carriers for the APIs though the lymphatic system, converting these compounds into ingestible formats that can be readily administered in capsules or liquid mixtures.
Zacks focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators (https://nnw.fm/HN4r3).
“Interest in using (DehydraTECH) extends across many categories beyond the primary pharmaceutical focus of the company from foods to beauty products and nutraceuticals, and across a range of formats from oral ingestible to oral buccal/sublingual to topical products,” Zacks notes in a news release issued Sept. 23 (https://nnw.fm/H4rQv).
But thus far, Lexaria’s testing has focused on potential uses of DehydraTECH in treating high blood pressure (hypertension) in combination with cannabidiol (“CBD”), as well as in battling viruses through combination with such antivirals as remdesivir and colchicine and in providing alternatives to tobacco smoking through nicotine replacement therapy oral pouches.
Clinical and preclinical studies have advanced Lexaria’s API toward commercialization in these areas, but DehydraTECH is already being used in CBD-based nutraceutical products distributed through retailers such as Albertson’s, Safeway and Hudson News stores.
Zacks notes the potential market reach of Lexaria’s technology if regulatory-approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances.
Lexaria’s use of the lymphatic system for bioavailability allows APIs to achieve more rapid delivery to the circulatory system and bypass the liver’s filtration mechanism, which digested medicines would normally be subject to. DehydraTECH’s lymph vessel delivery approach also has several advantages over digested medicines by decreasing concerns about taste, improving neurological delivery across the blood brain barrier, reducing the amount of drugs needed for usefulness, and decreasing the risk of side effects.
The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships.
“Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” CEO Chris Bunka said of the company’s brand partnerships earlier this summer (https://nnw.fm/XGjeV). “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share
- Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs
- Lexaria is also investigating alternatives to smoked or inhaled nicotine delivery to avoid lung harm, expanding the potential of its technology
- DehydraTECH’s lymph system delivery method alternative to the digestive system provides more rapid bioavailability and fewer side effects, as well as the potential for better delivery across the blood-brain barrier
- The relatively low-cost technology has the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships
Oral drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) has drawn the attention of Zacks Small-Cap Research analysts, who have initiated coverage of Lexaria with a valuation of $15 per share because of the company’s patent portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption technology and the multiple potential uses of the technology.
DehydraTECH pairs active pharmaceutical ingredients (“APIs”) with select long-chain fatty acid (“LCFAs”) oils that serve as carriers for the APIs though the lymphatic system, converting these compounds into ingestible formats that can be readily administered in capsules or liquid mixtures.
Zacks focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators (https://nnw.fm/HN4r3).
“Interest in using (DehydraTECH) extends across many categories beyond the primary pharmaceutical focus of the company from foods to beauty products and nutraceuticals, and across a range of formats from oral ingestible to oral buccal/sublingual to topical products,” Zacks notes in a news release issued Sept. 23 (https://nnw.fm/H4rQv).
But thus far, Lexaria’s testing has focused on potential uses of DehydraTECH in treating high blood pressure (hypertension) in combination with cannabidiol (“CBD”), as well as in battling viruses through combination with such antivirals as remdesivir and colchicine and in providing alternatives to tobacco smoking through nicotine replacement therapy oral pouches.
Clinical and preclinical studies have advanced Lexaria’s API toward commercialization in these areas, but DehydraTECH is already being used in CBD-based nutraceutical products distributed through retailers such as Albertson’s, Safeway and Hudson News stores.
Zacks notes the potential market reach of Lexaria’s technology if regulatory-approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances.
Lexaria’s use of the lymphatic system for bioavailability allows APIs to achieve more rapid delivery to the circulatory system and bypass the liver’s filtration mechanism, which digested medicines would normally be subject to. DehydraTECH’s lymph vessel delivery approach also has several advantages over digested medicines by decreasing concerns about taste, improving neurological delivery across the blood brain barrier, reducing the amount of drugs needed for usefulness, and decreasing the risk of side effects.
The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships.
“Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” CEO Chris Bunka said of the company’s brand partnerships earlier this summer (https://nnw.fm/XGjeV). “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼